John Lewicki

John joined Mereo as Chief Scientific Officer in July 2020. He has over 35 years of experience in the biotechnology industry.

John was President, CEO, and a board member of OncoMed Pharmaceuticals Inc. from March 2018 to April 2019. He joined as Senior Vice President of Research and Development in 2004 before assuming additional leadership roles.

Previously, John served as Vice President of Research, at Scios Inc where he co-discovered human B-type natriuretic peptide (BNP). John contributed to development of BNP into an FDA-approved treatment (Natrecor) for acute congestive heart failure.

John received his PhD from the University of California, San Diego. He has co-authored over 80 papers and is co-inventor on over 30 issued US patents.